| Identification | Back Directory | [Name]
Acetamide, 2-[(5-hydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-N-[[4-(trifluoromethyl)phenyl]methyl]- | [CAS]
2835447-74-8 | [Synonyms]
Acetamide, 2-[(5-hydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]-N-[[4-(trifluoromethyl)phenyl]methyl]- | [Molecular Formula]
C25H18F3NO5 | [MOL File]
2835447-74-8.mol | [Molecular Weight]
469.41 |
| Chemical Properties | Back Directory | [Boiling point ]
711.1±60.0 °C(predicted) | [density ]
1.401±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
6.19±0.40(predicted) |
| Hazard Information | Back Directory | [Uses]
YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model[1]. | [IC 50]
PPARγ: 1.72 μM (IC50); PPARγ: 0.62 μM (Ki) | [References]
[1] Ma L, et al., Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis. Eur J Med Chem. 2024 Oct 5;276:116728. DOI:10.1016/j.ejmech.2024.116728 |
|
|